Extensive immune response associated inflammation is the major reason for the pathological outcome of COVID-19 infection. Infliximab is an anti tumor necrosis factor (anti-TNF) drug that is used to reduce inflammation through TNF-α inhibition. Inhibition of main inflammatory cytokine such as TNF-α may has a potential effect in COVID-19 treatment. Here, we report the clinical outcome associated with Infliximab treatment in a 65-year-old woman with confirmed COVID-19 infection. Infliximab therapy was started on day 9th, patient demonstrated clinical improvement and recovery from COVID-19. Our findings suggest that the association of TNF-α inhibition and clinical management together contributes to COVID-19 patient survival.